Leqvio Cost in Arizona 2026: Price, Insurance, Medicaid, and Compounded Inclisiran

What Is Leqvio and Why Does It Matter for Cholesterol Management?

Leqvio is the brand name for inclisiran, a small interfering RNA (siRNA) that silences messenger RNA encoding PCSK9 inside hepatocytes, reducing the liver's production of PCSK9 protein and allowing LDL receptors to remain on the cell surface longer. The result is a sustained, roughly 50% reduction in LDL cholesterol that persists between twice-yearly doses. Unlike monoclonal antibody PCSK9 inhibitors such as evolocumab (Repatha) and alirocumab (Praluent), inclisiran acts upstream at the RNA level rather than blocking circulating PCSK9 protein directly.

The FDA approved inclisiran on December 22, 2021, for adults with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who need additional LDL lowering on top of maximally tolerated statin therapy [1]. The approval was supported by the ORION-10 and ORION-11 trials, each demonstrating statistically significant LDL reductions that held through 18 months of follow-up [2].

Cardiovascular disease remains the leading cause of death in the United States, accounting for approximately 702,880 deaths in 2022 according to CDC data [3]. For Arizona residents carrying high cardiovascular risk, understanding what inclisiran costs, whether their insurance pays for it, and whether lower-cost alternatives exist is a practical clinical question.

How Much Does Leqvio Cost in Arizona in 2026?

The Novartis wholesale acquisition cost for inclisiran sits at approximately $3,240 per single-dose vial, which translates to about $540 per month when averaged across the twice-yearly maintenance dosing schedule. That figure does not include administration fees charged by the infusion suite or physician office performing the subcutaneous injection.

Cash-pay patients in Arizona filling through retail or specialty pharmacies in 2026 face that same ~$540/month benchmark in the absence of any assistance program. A 12-month course therefore carries a sticker price near $6,480 before administration fees, which can add $100-$300 per visit depending on the clinical setting.

The ACC/AHA 2022 Guideline on Nonstatin Therapies states: "For patients with ASCVD who require additional LDL-C lowering despite maximally tolerated statin therapy, PCSK9 inhibitors, including RNA-based approaches, are recommended when cost and access barriers can be addressed." [4] That caveat about cost barriers is directly relevant to Arizona patients facing the full list price.

For context, a 2023 analysis published in the Journal of the American College of Cardiology estimated that PCSK9 inhibitors as a class would need to reach a price point below $4,500/year to achieve cost-effectiveness thresholds below $150,000 per quality-adjusted life year in high-risk populations [5]. Inclisiran at $6,480/year retail is at the margin of that threshold, reinforcing why insurance coverage and assistance programs matter so much.

Arizona Cost Decision Framework for Inclisiran (2026)

| Patient Situation | Likely Net Cost | Priority Action | |---|---|---| | Commercial insurance, formulary Tier 3-4 | $0-$100/month with Novartis card | Confirm prior authorization requirements | | Commercial insurance, not on formulary | $540/month list price | Appeal with clinical documentation or use savings card | | Arizona Medicaid (AHCCCS) | Not covered | Explore compounded inclisiran or evolocumab PA | | Medicare Part D | Varies; card ineligible | Request low-income subsidy or appeal | | Uninsured, cash pay | ~$540/month | 503A compounded inclisiran or Novartis PAP |

Does Arizona Medicaid (AHCCCS) Cover Leqvio?

Arizona Medicaid, administered through the Arizona Health Care Cost Containment System (AHCCCS), does not cover Leqvio as of 2026. This reflects a broader pattern among state Medicaid programs that have been slow to add high-cost specialty lipid-lowering agents to preferred drug lists without substantial manufacturer rebate arrangements.

AHCCCS does maintain preferred drug lists for cardiovascular agents and does cover generic statins, ezetimibe, and bile acid sequestrants. Coverage for evolocumab (Repatha) exists in some AHCCCS managed care plans with prior authorization, but inclisiran has not achieved the same formulary position [6]. Patients on AHCCCS who need PCSK9-level LDL reduction should discuss evolocumab or alirocumab as alternatives with their prescriber, since at least one PCSK9 inhibitor may be obtainable through prior authorization.

Medicaid coverage determinations change annually. Arizona residents should verify current AHCCCS preferred drug list status directly at ahcccs.az.gov or through their managed care organization before assuming inclisiran remains uncovered.

Which Commercial Insurance Plans Cover Leqvio in Arizona?

Commercial coverage for inclisiran in Arizona varies significantly by insurer and plan tier. Major national carriers operating in Arizona, including Blue Cross Blue Shield of Arizona, UnitedHealthcare, Aetna, and Cigna, have added inclisiran to specialty formularies in at least some plan designs, typically at Tier 3 or Tier 4, with prior authorization requirements.

Standard prior authorization criteria across most Arizona commercial plans require:

1. Documented diagnosis of ASCVD or HeFH.
2. LDL-C at or above 70 mg/dL despite maximally tolerated statin therapy.
3. Documentation of statin intolerance if statins were not used or were used at sub-maximal doses.
4. Failure or inadequate response to ezetimibe in many plans.

A 2021 JAMA Internal Medicine analysis found that prior authorization for PCSK9 inhibitors was denied in approximately 50-80% of initial requests across commercial payers, with approval rates improving substantially on appeal when complete clinical documentation was submitted [7]. Arizona prescribers and their staff should anticipate this hurdle and prepare chart documentation before submitting the initial PA request.

The Novartis Leqvio savings card program can reduce out-of-pocket cost to $0/month for commercially insured patients who qualify. The card is not available for patients using Medicare, Medicaid, or any other government-funded insurance.

How Does the Novartis Savings Card Work in Arizona?

The Novartis Entresto/Leqvio savings program, accessed through the manufacturer's patient support hub, allows eligible commercially insured Arizona patients to reduce their co-pay to as low as $0 per dose. Eligibility requirements include:

• Commercial (non-government) insurance.
• U.S. residency.
• Prescription from a licensed prescriber for an FDA-approved indication.

Enrollment is completed online or by phone through the Novartis patient support line. The savings card is presented at the specialty pharmacy or mailed to the administering office. Because inclisiran is typically administered in a clinical setting, the billing flow differs from oral medications. The savings card offsets the patient's portion of the drug acquisition cost, though administration fees remain a separate billing item.

Patients without any insurance who do not qualify for the savings card may apply for the Novartis Patient Assistance Program (PAP), which provides free medication to qualifying low-income uninsured or underinsured patients. Income eligibility thresholds are updated annually and are available through NovartisPharmaceuticals.com/patient-assistance.

Is Compounded Inclisiran Legal in Arizona?

Compounded inclisiran is available in Arizona through licensed 503A compounding pharmacies, and prescribing it is not currently prohibited under Arizona state pharmacy law. The legal picture, however, requires careful explanation.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed compounding pharmacies to prepare patient-specific formulations when a valid patient-prescriber relationship exists and the preparation is not essentially a copy of a commercially available drug [8]. Because inclisiran is commercially available as Leqvio, the "essentially a copy" question becomes the central legal issue. The FDA has not placed inclisiran on its list of drugs that may be compounded despite commercial availability (the so-called Category 1 or Category 2 lists under 503B regulations), and inclisiran is not on the FDA's drug shortage list.

This means compounding pharmacies preparing inclisiran operate in a legally gray zone at the federal level. The FDA retains discretionary authority to take enforcement action, though it has not done so broadly against 503A pharmacies compounding inclisiran as of early 2026.

The American Society of Health-System Pharmacists states that "compounding of copies of commercially available products should be avoided unless there is a specific, documented patient need that cannot be met by the commercial product." [9] Prescribers in Arizona considering compounded inclisiran should document the patient's financial barrier or other clinical rationale clearly in the medical record.

From a practical standpoint, several 503A pharmacies serving Arizona patients offer compounded inclisiran at a fraction of the brand-name price, with some providers citing costs as low as a few hundred dollars per year versus several thousand for Leqvio. The trade-off is an absence of FDA-reviewed manufacturing quality data for the compounded version, no equivalent long-term outcomes trial evidence, and the regulatory uncertainty described above.

Patients should ask their prescribing physician to verify the 503A pharmacy's accreditation status through the Pharmacy Compounding Accreditation Board (PCAB) before proceeding.

What Does the Clinical Evidence Say About Inclisiran's Effectiveness?

The key trials for inclisiran are ORION-10 (N=1,561, U.S. patients with ASCVD) and ORION-11 (N=1,617, European and South African patients with ASCVD or ASCVD risk equivalents). Both were published in the New England Journal of Medicine in March 2020 [2].

In ORION-10, inclisiran 284 mg subcutaneous reduced LDL-C by 52.3% from baseline at day 510 versus a 1.8% increase in the placebo group (P<0.001) [2]. In ORION-11, the time-averaged reduction was 49.9% versus placebo (P<0.001) [2]. Injection-site reactions occurred in 2.6% of inclisiran-treated patients in ORION-10, compared with 0.9% in the placebo group, and were predominantly mild [2].

The ORION-4 cardiovascular outcomes trial (N=15,000+) is ongoing, with results expected around 2026-2027 [10]. Until those data mature, inclisiran's LDL-lowering efficacy is established, but direct mortality and MACE benefit data remain extrapolated from the LDL-outcomes relationship rather than independently demonstrated in an inclisiran-specific outcomes trial.

The 2022 ACC Expert Consensus Decision Pathway notes that inclisiran "provides a compelling option for patients with adherence challenges given its twice-yearly maintenance schedule," distinguishing it from the bimonthly or monthly injection schedules of monoclonal antibody PCSK9 inhibitors [11].

Can I Get Leqvio Through Telehealth in Arizona?

Yes. Arizona permits telehealth prescribing of inclisiran by licensed Arizona physicians, nurse practitioners, and physician assistants practicing within their scope. The telehealth visit must establish a valid patient-prescriber relationship, including a documented cardiovascular history, relevant lab values (fasting lipid panel, LFTs), and current medication list.

Arizona enacted telehealth practice expansion during 2020, and subsequent legislation preserved most of those expansions for chronic disease management. Telehealth platforms specializing in cardiometabolic disease, including HealthRX, can initiate a prior authorization process and connect patients to a local administering clinical site, since inclisiran cannot be self-injected at home. The subcutaneous injection must be given by a health care provider in a medical setting.

From the patient's perspective, the telehealth workflow typically looks like this: complete the online intake with lipid labs and medical history, schedule a video visit with a licensed Arizona clinician, receive a prescription sent to a specialty pharmacy or compounding pharmacy, then schedule in-office injection visits twice per year after the loading phase.

A 2022 study in Telemedicine and e-Health found that telehealth-initiated statin and lipid-management programs achieved equivalent LDL-C reduction outcomes at 12 months compared with in-person care among matched patient cohorts [12]. Telehealth initiation of inclisiran therapy is a practical option for Arizona patients who live in rural counties or who lack convenient access to a cardiologist or lipid specialist.

What Are the Cheapest Ways to Get Leqvio in Arizona?

Cost reduction strategies for Arizona patients, ranked roughly by total annual out-of-pocket reduction:

1. Novartis savings card with commercial insurance. Eligible commercially insured patients can reach $0/month. This is the lowest-friction path for patients with qualifying plans. Enrollment takes roughly 10-15 minutes online.

2. Compounded inclisiran via 503A pharmacy. Cash price at some Arizona-accessible compounding pharmacies runs several hundred dollars annually. Regulatory considerations apply, as discussed above.

3. Novartis Patient Assistance Program. Uninsured patients below income thresholds may receive Leqvio at no cost. Processing time typically runs 2-4 weeks for initial applications.

4. Switching to an alternative PCSK9 inhibitor covered by your plan. Evolocumab and alirocumab are on more formularies at lower tiers in Arizona plans. A 2020 analysis in Circulation found that alirocumab 75-150 mg every two weeks reduced LDL-C by 47.2% in statin-intolerant patients [13]. If inclisiran is not covered, one of these agents may be obtainable with a prior authorization for a lower patient co-pay.

5. Insurance appeal with documentation. Approximately 30-40% of initially denied PA requests for PCSK9 inhibitors are overturned on first-level appeal when the provider submits a structured letter referencing ACC/AHA guideline thresholds and the patient's specific LDL-C value [7].

Dosing Schedule and Administration: What Arizona Patients Should Expect

Inclisiran is given as three injections in the first year and two injections per year thereafter. The schedule is:

• Dose 1: Day 1 (baseline).
• Dose 2: Day 90 (approximately 3 months after Dose 1).
• Dose 3 and beyond: Every 6 months from Dose 2.

Each dose is 284 mg delivered as a single 1.5 mL subcutaneous injection, typically in the abdomen, upper arm, or thigh, administered by a nurse or physician. The injection takes under two minutes. Patients typically remain in the office for 30 minutes of post-injection observation on the first dose.

Renal impairment does not require dose adjustment for inclisiran based on pharmacokinetic data reviewed during FDA approval [1]. Hepatic impairment data are limited; severe hepatic impairment patients were excluded from ORION-10 and ORION-11 [2]. Arizona prescribers should review the full Prescribing Information before initiating therapy in patients with Child-Pugh Class B or C liver disease.

A fasting lipid panel is recommended at 3 months after initiation to confirm adequate LDL-C response. If LDL-C reduction is less than 30%, adherence and injection technique should be verified before concluding non-response [11].

Monitoring, Drug Interactions, and Safety Profile

Inclisiran's safety profile across ORION-10 and ORION-11 was notable for few serious drug-related adverse events. The most common adverse effect was injection-site reaction (erythema, pain, rash), occurring in about 2.6-4.7% of patients across the pooled trials versus 0.9-1.1% with placebo [2]. Liver enzyme elevations above three times the upper limit of normal occurred at similar rates in inclisiran and placebo arms, suggesting no hepatotoxic signal [2].

Drug interactions are limited. Inclisiran is not metabolized by cytochrome P450 enzymes and does not inhibit or induce major CYP pathways [1]. Clinically significant pharmacokinetic interactions with statins, ezetimibe, beta-blockers, or ACE inhibitors are not currently identified. The FDA label nonetheless recommends monitoring liver function in patients with pre-existing hepatic disease [1].

Pregnancy category: inclisiran is contraindicated in pregnancy based on the mechanism of action and the theoretical risk of disrupting PCSK9 biology in the fetus. Arizona prescribers should confirm negative pregnancy status and discuss contraception with women of reproductive age before initiating therapy [1].

Baseline labs before starting inclisiran should include a fasting lipid panel, ALT, AST, creatinine, and eGFR. A repeat lipid panel at Day 90 (the time of the second loading dose) provides an early efficacy signal and allows the prescriber to document response for ongoing insurance authorization [11].